CD4 and mature T-cell and NK-cell non-Hodgkin lymphoma: Engineered anti-CD4 CAR CD8+ T cells displayed a significant anti-leukemic effect in vivo in a xenograft NSG mouse engrafted with the KARPAS 299 aggressive PTCL cell line.